About Uncharacterized protein C12orf50
Uncharacterized protein C12orf50 (C12orf50) is a protein
from Homo sapiens identified by UniProt accession
Q8NA57, 414 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Uncharacterized protein C12orf50 |
|---|
| UniProt accession | Q8NA57 |
|---|
| Gene | C12orf50 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 414 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (8)
Diseases linked to this target (Open Targets).
- hair colour measurement · score 0.37
- type 2 diabetes mellitus · score 0.24
- sodium measurement · score 0.17
- systolic blood pressure · score 0.17
- reticulocyte measurement · score 0.10
- hair color · score 0.05
- Abnormal sperm morphology · score 0.01
- juvenile idiopathic arthritis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NA57-F1 | alphafold | PREDICTED | 53.05 | — |
Amino-acid sequence (414 residues)
MEMQQNCSIS CFWETQPLGC VKISCIFYHS KPRNINGLFL PPSSNITLQK EIQEGIPLQS QSQEPLKPQE NISRPIHHPL VLKTNFEEEE EVDEQNDASS LWTKTPEEIE EKRAIKEMCY KSGEYYRFHT PPDILSSKSM TPTAEKQLEK PLENGSELQE GDSLTVPTKL SQYERQGEIK TSLHGKPKTD IAAFENGGGD CYVPQRVIFL GVDESEALTE EKEITISKCS NTKDNKDSPH PKHSLTTRLV PTTHVLNATE NISMKCREDP SSMNDVQPVK KPHFKGVKKR KWIYDEPQNF PNSGMQRAVQ APRPQNKMSY HRNNKNRNAE NASYIHVQRD AVRTVALNAP SRSRPTHGSY NKVHANREPK PNLSPDKYTS TSYNDSAWRK RIPFSKTYSK SEKIYPEPRR NGSK
Explore Uncharacterized protein C12orf50 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets